Skip to content

Source filing unavailable

Q2 2016 · —
Revenue—
Net Income-$6.06Mno prior Q2 2015 on fileN/M vs Q1 2016
EPS Diluted-$25.30no prior Q2 2015 on fileN/M vs Q1 2016

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

no prior Q2 2015 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR